Pacira BioSciences’ Acquisition of Flexion Therapeutics

Perkins Coie advised Pacira BioSciences on the deal.

Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, announced its definitive agreement to acquire Flexion Therapeutics, Inc., subject to customary closing conditions, including receipt of required regulatory approvals.

Under the terms of the deal, Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash. Flexion’s innovative non-opioid portfolio directly aligns with Pacira’s mission to provide an opioid alternative to as many patients as possible and address medical needs along the neural pain pathway. Flexion is focused on the development and commercialization of novel, local non-opioid therapies for the treatment of patients with musculoskeletal conditions, including osteoarthritis, postsurgical pain, and low back pain.

The Perkins Coie deal team representing Pacira BioSciences in the transaction is led by Denver partners Jason Day (Picture) and Jeff Beuche, counsel Jonathan Schulman and David Martinez, and associate Tessa Bell.

Involved fees earner: Tessa Bell – Perkins Coie; Jeffrey Beuche – Perkins Coie; Jason Day – Perkins Coie; David Martinez – Perkins Coie; Jonathan Schulman – Perkins Coie;

Law Firms: Perkins Coie;

Clients: Pacira BioSciences;

Author: Martina Bellini